Nobel Prize Winner Professor Aaron Ciechanover appointed senior member on the advisory committee of Panaxia Pharmaceutical

Dr. Dadi Segal, CEO and founder of Panaxia: "The entrance of a world-renowned scientist places Panaxia Pharmaceutical as a leading contender in the industry, and acts as a vote of confidence in the company's capabilities."

LOD, Israel, Feb. 19, 2019 /PRNewswire/ -- The pharma company, Panaxia Pharmaceutical Industries LTD, an Israeli pharmaceutical cannabis company, announced today that Nobel Prize winner in chemistry, Prof. Aaron Ciechanover, 72, has been appointed as a senior member on the advisory committee of Panaxia Pharmaceutical's directorate.

Panaxia Israel is part of the pharmaceutical group of the Segal family, operating over four decades, manufacturing over 600 different pharmaceutical products distributed in over 30 countries. Panaxia Pharmaceutical was founded by Dr. Dadi Segal, Dr.Eran Goldberg and Assi Rotbart, LL.b, form the group's cannabis division. The company offers a variety of Cannabinoid medical/ pharmaceutical products. The sister-division of North America manufactures over 60 pharmaceutical products based on medical cannabis, including sublingual tablets, oral tablets, oils, inhalers, intended to treat conditions such as post-traumatic stress, cancer, chronic pains, epilepsy, burns, and other medical conditions.

Prof. Ciechanover: "I am pleased to join a pharma company with products based on pharmaceutical cannabis. This has raised the bar for innovation together with science-based knowledge and the adoption of advanced technologies. This will provide patients whom are suffering from various illnesses, a real therapeutic treatment."

Dr. Dadi Segal, CEO and Founder of Panaxia, added that "the entrance of a world-renowned scientist places Panaxia Pharmaceutical as a leading contender in the industry, and acts as a vote of confidence in the company's capabilities. There is no doubt he will be a significant contributor in the research we conduct to make pharmaceutical cannabis accessible to a greater number of patients and help treat a wider range of illnesses."

The pharmaceutical-cannabis market is a 13-Billion-dollar annual market, growing 30% every year. Panaxia Israel is the largest pharmaceutical-cannabis manufacturer in Israel today manufacturing over 50,000 products per month in the Israeli market alone. The company operates in the field of cannabis, adhering strictly to the highest medical standards in Israel and the world, manufactures the majority of pharmaceutical-cannabis brands in Israel, including premium brand "Axiban" in collaboration with Rafa Pharmaceutical. Panaxia group is the first company to receive a permit to manufacture medication based on pharmaceutical cannabis (IMC-GMP standard).

For further info: Steve Levy,
Tel # +1-305-933-4646 / E-mail: [email protected]

SOURCE Panaxia Pharmaceutical Industries

Related Links

https://panaxia.co.il/